FIELD: medicine.
SUBSTANCE: invention relates to use of a combination comprising (a) B7-H3 antibody or antigen-binding fragment thereof, wherein said B7-H3 antibody or antigen-binding fragment thereof is administered in a dose of about 1–15 mg/kg of body weight, and (b) an anti-PD-1 antibody or antigen-binding fragment thereof for treating cancer in a subject in need thereof.
EFFECT: invention provides intensified anticancer activity.
46 cl, 1 ex, 6 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| IMPROVED METHODS OF TREATING VASCULARISED MALIGNANT TUMORS | 2015 |
|
RU2692248C2 |
| SPECIFIC LINKING AGENTS AGAINST B7-H1 | 2010 |
|
RU2571204C2 |
| ANTIBODY AGAINST B7-H3, ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL USE | 2018 |
|
RU2765306C2 |
| ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1 | 2012 |
|
RU2625034C2 |
| METHODS OF TREATING CANCER USING PD-1 AXIS BINDING AND VEGF ANTAGONISTS | 2013 |
|
RU2689760C2 |
| ANTI-PD-L1 ANTIBODIES AND METHODS FOR THEIR DIAGNOSTIC USE | 2015 |
|
RU2715038C2 |
| ANTI-B7-H3-ANTIBODY | 2012 |
|
RU2668170C2 |
| SPECIFIC BINDING AGENTS AGAINST B7-H1 | 2010 |
|
RU2706200C2 |
| ANTIBODIES TO H7CR | 2013 |
|
RU2650756C2 |
| ANTI-PD-L1 ANTIBODY AND ITS USE | 2020 |
|
RU2783685C2 |
